Sarepta Therapeutics Inc. (srpt 1.25 09/15/27)
13F holders, Q2 2026 (June 30)5holders −1
1new positions
2sold out
$0.94avg. 13F price*
At the end of Q2 2026, 5 institutions reported holding Sarepta Therapeutics Inc. (srpt 1.25 09/15/27) in their 13F filings, down 1 from Q1 2026. 1 opened new positions and 2 sold out. The largest holders were Financial Consulate, Inc. ($991K), HB Wealth Management, LLC ($523K) and Greenspring Advisors, LLC ($13K).
- Company
- Sarepta Therapeutics Inc. (srpt 1.25 09/15/27)
- CUSIP
- 803607AD2
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $13K |
| Exits | 2 | $3.2M |
All 13F filers, Q1 2026 → Q2 2026: 62,000 shares bought and 3,527,000 shares sold, net −3,465,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Financial Consulate, Inc. | 0.11% | Add +4.8% | 1,047,000 | $991K |
| HB Wealth Management, LLC | 0.00% | No change | 555,000 | $523K |
| Greenspring Advisors, LLC | 0.00% | New | 14,000 | $13K |
| Cambridge Investment Research Advisors, Inc. | 0.00% | No change | 13,000 | $12K |
| Rothschild Investment LLC | 0.00% | No change | 1,000 | $943 |
"% of holder's portfolio" is SAREPTA THERAPEUTICS INC (SRPT 1.25 09/15/27)'s weight in each manager's 13F, not the share of Sarepta Therapeutics Inc. (srpt 1.25 09/15/27) the manager owns.